Harvey J. Iii Clewell
#155,456
Most Influential Person Now
Harvey J. Iii Clewell's AcademicInfluence.com Rankings
Harvey J. Iii Clewellmedical Degrees
Medical
#3045
World Rank
#3496
Historical Rank
Toxicology
#44
World Rank
#48
Historical Rank
Download Badge
Medical Chemistry
Why Is Harvey J. Iii Clewell Influential?
(Suggest an Edit or Addition)Harvey J. Iii Clewell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. (1987) (672)
- Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. (2012) (352)
- Acrylamide: Review of Toxicity Data and Dose-Response Analyses for Cancer and Noncancer Effects (2006) (271)
- Risk Assessment Extrapolations and Physiological Modeling (1985) (243)
- Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. (2010) (238)
- A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. (2012) (214)
- Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven Framework (2013) (209)
- Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results (2012) (195)
- Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing (2015) (190)
- A physiologically based toxicokinetic model for the uptake and disposition of waterborne organic chemicals in fish. (1990) (186)
- Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. (2004) (186)
- A physiologically based simulation approach for determining metabolic constants from gas uptake data. (1986) (183)
- Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. (2006) (179)
- Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. (1986) (162)
- A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. (2007) (160)
- PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. (2010) (159)
- Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. (2005) (156)
- Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. (2005) (156)
- Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. (1999) (155)
- Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. (2000) (152)
- Quantitative interpretation of human biomonitoring data. (2008) (145)
- Consensus report on the future of animal-free systemic toxicity testing. (2014) (144)
- Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. (2013) (144)
- Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling (2007) (142)
- Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK) (2015) (137)
- Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. (1989) (136)
- Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics (1999) (135)
- Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. (1991) (132)
- Development and specification of physiologically based pharmacokinetic models for use in risk assessment. (2008) (131)
- Dermal absorption of organic chemical vapors in rats and humans. (1990) (125)
- PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. (2014) (120)
- Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. (2013) (114)
- Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. (2011) (114)
- Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. (2010) (113)
- Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. (2008) (110)
- Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry (2002) (110)
- Development of Pbpk Models for Pfoa and Pfos for Human Pregnancy and Lactation Life Stages (2013) (106)
- Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. (1987) (104)
- The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. (2012) (103)
- Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. (1995) (103)
- Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. (2001) (101)
- Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. (1996) (100)
- Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. (2008) (98)
- Physiologically Based Pharmacokinetic Modeling : Science and Applications (2005) (98)
- A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. (1988) (98)
- Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform (2006) (97)
- Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. (2011) (97)
- Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. (2011) (96)
- Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. (2008) (92)
- A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. (2001) (91)
- A physiological pharmacokinetic model for dermal absorption of vapors in the rat. (1986) (88)
- Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. (2001) (87)
- Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. (1990) (86)
- Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropyfluorophosphate (1990) (84)
- In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI (2012) (84)
- PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS (2002) (83)
- Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. (2003) (82)
- Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. (1994) (80)
- Analysis of genomic dose‐response information on arsenic to inform key events in a mode of action for carcinogenicity (2009) (78)
- Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. (2012) (78)
- Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. (2009) (78)
- Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. (1994) (77)
- Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). (1993) (73)
- An Analysis of N-Acetylcysteine Treatment for Acetaminophen Overdose Using a Systems Model of Drug-Induced Liver Injury (2012) (72)
- The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. (2007) (71)
- Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. (2014) (70)
- Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. (1995) (69)
- Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. (2010) (69)
- Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. (2008) (69)
- In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. (2012) (68)
- Application of pharmacokinetic data to the risk assessment of inhaled manganese. (2006) (67)
- Risk assessment of chemical mixtures: biologic and toxicologic issues. (1993) (67)
- Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. (1987) (66)
- Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. (2002) (65)
- Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. (2011) (65)
- Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat (1990) (63)
- A physiologically based pharmacokinetic model for retinoic acid and its metabolites. (1997) (61)
- An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. (2002) (61)
- Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. (2012) (61)
- Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. (2012) (58)
- Genetic polymorphisms in assessing interindividual variability in delivered dose. (2002) (58)
- Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. (2000) (58)
- Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. (2006) (57)
- Hormesis and Adaptive Cellular Control Systems (2008) (56)
- Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. (2012) (56)
- Reanalysis of dose-response data from the Iraqi methylmercury poisoning episode. (1995) (55)
- Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. (2014) (55)
- Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage (2007) (55)
- Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid. (2000) (53)
- Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. (2008) (53)
- The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. (1995) (53)
- Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. (2006) (53)
- Use of Markov Chain Monte Carlo Analysis with a Physiologically‐Based Pharmacokinetic Model of Methylmercury to Estimate Exposures in U.S. Women of Childbearing Age (2007) (52)
- Molecular Signaling Network Motifs Provide a Mechanistic Basis for Cellular Threshold Responses (2014) (50)
- Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. (1996) (50)
- Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. (1995) (49)
- The use of non-tumor data in cancer risk assessment: reflections on butadiene, vinyl chloride, and benzene. (2003) (48)
- Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. (2009) (47)
- Development of a Screening Approach to Interpret Human Biomonitoring Data on Volatile Organic Compounds: Reverse Dosimetry on Biomonitoring Data for Trichloroethylene (2007) (47)
- Physiologically based pharmacokinetic analyses of simple mixtures. (1994) (47)
- Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. (1988) (47)
- Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeks. (2011) (46)
- Preclinical Development Handbook: ADME and Biopharmaceutical Properties (2007) (45)
- Pharmacokinetic Modeling of Manganese in the Rat IV: Assessing Factors that Contribute to Brain Accumulation During Inhalation Exposure (2008) (45)
- Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. (2006) (45)
- Physiologically based pharmacokinetic/toxicokinetic modeling. (2012) (44)
- Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". (2011) (44)
- Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. (2010) (44)
- Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics? (2013) (44)
- Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene (2005) (44)
- Determination of an Occupational Exposure Guideline for Manganese Using the Benchmark Method (2003) (44)
- Dose-response for assessing the cancer risk of inorganic arsenic in drinking water: the scientific basis for use of a threshold approach (2019) (42)
- Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. (2008) (42)
- Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study (1995) (39)
- In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. (2013) (39)
- Physiologically-Based Pharmacokinetic Modeling and Bioactivation of Xenobiotics (1994) (39)
- Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes (1998) (39)
- Toxicant-inflicted injury and stimulated tissue repair are opposing toxicodynamic forces in predictive toxicology. (1999) (38)
- Bayesian Calibration of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Carbaryl Cholinesterase Inhibition (2008) (38)
- Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse (2014) (37)
- Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. (1994) (36)
- Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. (1990) (36)
- Harmonization: Developing Consistent Guidelines for Applying Mode of Action and Dosimetry Information to Cancer and Noncancer Risk Assessment (1998) (36)
- Determination of a site-specific reference dose for methylmercury for fish-eating populations. (2000) (36)
- Pharmacokinetic Modeling of Manganese. I. Dose Dependencies of Uptake and Elimination (2007) (36)
- Effects of endogenous formaldehyde in nasal tissues on inhaled formaldehyde dosimetry predictions in the rat, monkey, and human nasal passages. (2014) (35)
- Pharmacokinetic Modeling of Manganese. III. Physiological Approaches Accounting for Background and Tracer Kinetics (2007) (35)
- Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. (1994) (35)
- Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. (1997) (34)
- Quantitative in vitro to in vivo extrapolation (QIVIVE): An essential element for in vitro-based risk assessment. (2015) (33)
- Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. (1993) (33)
- Biologically motivated models for chemical risk assessment. (1989) (33)
- Application of Physiological Computational Fluid Dynamics Models to Predict Interspecies Nasal Dosimetry of Inhaled Acrolein (2008) (33)
- Can the observed association between serum perfluoroalkyl substances and delayed menarche be explained on the basis of puberty-related changes in physiology and pharmacokinetics? (2015) (33)
- Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene (2004) (33)
- Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study. (2015) (32)
- Bayesian Estimation of Pharmacokinetic and Pharmacodynamic Parameters in a Mode‐of‐Action‐Based Cancer Risk Assessment for Chloroform (2007) (32)
- Derivation of a human equivalent concentration for n-butanol using a physiologically based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid. (2005) (32)
- A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry (2014) (31)
- On the incorporation of chemical-specific information in risk assessment. (2008) (31)
- Allometric scaling of pegylated liposomal anticancer drugs (2011) (31)
- Evaluating Pharmacokinetic and Pharmacodynamic Interactions with Computational Models in Supporting Cumulative Risk Assessment (2011) (30)
- Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. (2009) (30)
- Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. (2010) (29)
- The application of PBPK models in estimating human brain tissue manganese concentrations (2017) (29)
- Quantitative bias analysis for epidemiological associations of perfluoroalkyl substance serum concentrations and early onset of menopause. (2017) (29)
- Dermal absorption of dihalomethane vapors. (1985) (29)
- Data for Physiologically Based Pharmacokinetic Modeling in Neonatal Animals: Physiological Parameters in Mice and Sprague-Dawley Rats (2004) (28)
- Pharmacokinetic Modeling of Manganese. II. Hepatic Processing After Ingestion and Inhalation (2007) (28)
- Requirements for a Biologically Realistic Cancer Risk Assessment for Inorganic Arsenic (1999) (28)
- Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. (2004) (28)
- The impact of recent advances in research on arsenic cancer risk assessment. (2014) (28)
- Application of a Physiologically Based Pharmacokinetic Model for Reference Dose and Reference Concentration Estimation for Acetone (2003) (28)
- Excretion of Di-2-ethylhexyl phthalate (DEHP) metabolites in urine is related to body mass index because of higher energy intake in the overweight and obese. (2018) (28)
- Evaluation of gene expression changes in human primary uroepithelial cells following 24‐Hr exposures to inorganic arsenic and its methylated metabolites (2013) (28)
- Multi-Dose-Route, Multi-Species Pharmacokinetic Models for Manganese and Their Use in Risk Assessment (2010) (27)
- Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). (2019) (26)
- Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans (2019) (26)
- Use of mode of action in risk assessment: past, present, and future. (2005) (26)
- Cross-species transcriptomic analysis of mouse and rat lung exposed to chloroprene. (2013) (26)
- Determination of Human Hepatic CYP2C8 and CYP1A2 Age-Dependent Expression to Support Human Health Risk Assessment for Early Ages (2017) (26)
- Kinetics of Water Vapor Sorption in Stratum Corneum (1994) (25)
- Making sense of human biomonitoring data: Findings and recommendations of a workshop (2007) (25)
- Quantitative Estimates of Risk for Noncancer Endpoints (2005) (24)
- Challenges in the application of quantitative approaches in risk assessment: a case study with di-(2-ethylhexyl)phthalate (2011) (24)
- Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop (2019) (23)
- A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben. (2015) (23)
- Using exposure prediction tools to link exposure and dosimetry for risk-based decisions: A case study with phthalates (2017) (23)
- PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human (2016) (23)
- Determination of a site-specific reference dose for methylmercury for fish-eating populations (2000) (23)
- Application of a multi-route physiologically based pharmacokinetic model for manganese to evaluate dose-dependent neurological effects in monkeys. (2012) (22)
- Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. (2018) (22)
- Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials (2020) (22)
- Transcriptional responses in the rat nasal epithelium following subchronic inhalation of naphthalene vapor. (2014) (22)
- Implementation of EPA Revised Cancer Assessment Guidelines: Incorporation of Mechanistic and Pharmacokinetic Data. (1997) (22)
- Development of multi-route physiologically-based pharmacokinetic models for ethanol in the adult, pregnant, and neonatal rat (2012) (22)
- Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors. (1997) (21)
- Dose-dependence of chemical carcinogenicity: Biological mechanisms for thresholds and implications for risk assessment. (2019) (21)
- Incorporation of Pharmacokinetic and Pharmacodynamic Data into Risk Assessments (2004) (20)
- High-throughput in-silico prediction of ionization equilibria for pharmacokinetic modeling. (2018) (20)
- A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair (2012) (20)
- Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. (2007) (20)
- Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT—Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment (2012) (18)
- Development of an integrated multi-species and multi-dose route PBPK model for volatile methyl siloxanes - D4 and D5. (2016) (18)
- Fluid Dynamic Modeling to Support the Development of Flow-Based Hepatocyte Culture Systems for Metabolism Studies (2016) (18)
- How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review. (2008) (18)
- Cancer and non‐cancer risk assessment should be harmonized (1997) (18)
- EFSA's 21st Scientific Colloquium on Harmonisation of human and ecological risk assessment of combined exposure to multiple chemicals (2015) (17)
- Modeling the effect of succimer (DMSA; dimercaptosuccinic acid) chelation therapy in patients poisoned by lead (2017) (17)
- Derivation of an Inhalation Reference Concentration Based upon Olfactory Neuronal Loss in Male Rats following Subchronic Acetaldehyde Inhalation (2008) (16)
- A Pharmacokinetic Model of the Intracellular Dosimetry of Inhaled Nickel (2007) (16)
- Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver (2017) (16)
- Evaluation of a predictive in vitro Leydig cell assay for anti-androgenicity of phthalate esters in the rat. (2013) (16)
- Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation. (2019) (15)
- Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop. (2019) (15)
- Incorporating biological information in quantitative risk assessment: an example with methylene chloride. (1995) (15)
- A tissue dose‐based comparative exposure assessment of manganese using physiologically based pharmacokinetic modeling—The importance of homeostatic control for an essential metal (2017) (14)
- An Alternative Exact Solution of the Two‐Stage Clonal Growth Model of Cancer (1999) (14)
- Kinetics of water vapor sorption in porcine stratum corneum. (1994) (14)
- Pharmacokinetic bias analysis of the epidemiological associations between serum polybrominated diphenyl ether (BDE-47) and timing of menarche. (2016) (13)
- Pharmacokinetic Interactions of Mixtures (1984) (13)
- Derivation of inhalation toxicity reference values for propylene oxide using mode of action analysis: Example of a threshold carcinogen (2009) (13)
- Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling (2020) (13)
- Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling (2020) (13)
- Interspecies Dose Extrapolation for Inhaled Dimethyl Sulfate: A PBPK Model-Based Analysis using Nasal Cavity N7-Methylguanine Adducts (2004) (13)
- Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. (2020) (13)
- p53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene. (2011) (13)
- Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms (2021) (13)
- Physiologically Based Pharmacokinetic Modeling: A Tool for Understanding ADMET Properties and Extrapolating to Human (2013) (12)
- Time- and concentration-dependent genomic responses of the rat airway to inhaled nickel subsulfide. (2014) (12)
- In Vitro – In Vivo Extrapolation (2014) (12)
- New Framework for a Non-Animal Approach Adequately Assures the Safety of Cosmetic Ingredients - A Case Study on Caffeine. (2021) (12)
- Introduction: A Historical Perspective of the Development and Applications of PBPK Models (2005) (12)
- Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. (2003) (11)
- Kinetic modeling of β-chloroprene metabolism: Probabilistic in vitro-in vivo extrapolation of metabolism in the lung, liver and kidneys of mice, rats and humans. (2012) (11)
- Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic. (2014) (11)
- Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use. (2017) (11)
- Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment (2002) (11)
- Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. (2013) (11)
- Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation (2016) (11)
- A preliminary regional PBPK model of lung metabolism for improving species dependent descriptions of 1,3-butadiene and its metabolites. (2015) (11)
- COMPARING RESPIRATORY-TRACT AND HEPATIC EXPOSURE-DOSE RELATIONSHIPS FOR METABOLIZED INHALED VAPORS: A PHARMACOKINETIC ANALYSIS (2002) (10)
- Chemical Risk Analysis: A Practical Handbook (2002) (10)
- The Contribution of Peroxisome Proliferator-Activated Receptor Alpha to the Relationship Between Toxicokinetics and Toxicodynamics of Trichloroethylene. (2015) (10)
- Improving toxicology testing protocols using computer simulations. (1989) (9)
- Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. (2008) (9)
- An improved approximation to the exact solution of the two-stage clonal growth model of cancer. (1995) (9)
- Refinement of the oral exposure description in the cyclic siloxane PBPK model for rats and humans: Implications for exposure assessment. (2017) (9)
- Quantitative bias analysis of the association of type 2 diabetes mellitus with 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153). (2019) (8)
- Improving the Development and Use of Biologically Based Dose Response Models (BBDR) in Risk Assessment (2001) (8)
- Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system. (2019) (8)
- Incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene (2019) (8)
- An Objective Uncertainty Factor Adjustment for Methyl mercury Pharmacokinetic Variability (2002) (8)
- Development of a physiologically based pharmacokinetic model of diisononyl phthalate (DiNP) in pregnant rat and human (2020) (8)
- PBPK-Based Probabilistic Risk Assessment for Total Chlorotriazines in Drinking Water (2016) (8)
- Application of the adverse outcome pathway (AOP) approach to inform mode of action (MOA): A case study with inorganic arsenic (2018) (8)
- A Multiple Dose-Route Physiological Pharmacokinetic Model for Volatile Chemicals Using ACSL/PC, (1986) (8)
- Response to Comments by Caldwell et al. on Article “Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene” (2006) (8)
- Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. (2019) (8)
- An evaluation of the USEPA Proposed Approaches for applying a biologically based dose‐response model in a risk assessment for perchlorate in drinking water (2019) (7)
- Using a physiologically based pharmacokinetic model to link urinary biomarker concentrations to dietary exposure of perchlorate. (2012) (7)
- Assessing children's exposure to manganese in drinking water using a PBPK model. (2019) (7)
- Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. (2014) (7)
- Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures. (2021) (7)
- Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modeling (2016) (7)
- Evaluation of gene expression changes in human primary lung epithelial cells following 24‐hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide (2015) (6)
- Toxicokinetics: an analytical tool for assessing chemical hazards to man. (1988) (6)
- Mode of Action Studies for Assessing Carcinogenic Risks Posed by Inorganic Arsenic (1999) (6)
- Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment (2021) (6)
- The perils and promise of modern risk assessment: the example of trichloroethylene. (2004) (6)
- A model of functional thyroid disease status over the lifetime (2019) (6)
- Ground contamination by fuel jettisoned from aircraft in flight (1983) (6)
- Application of the Risk Assessment Approaches in the USEPA Proposed Cancer Guidelines to Inorganic Arsenic (1999) (5)
- Pharmacokinetic bias analysis of an association between clinical thyroid disease and two perfluoroalkyl substances. (2020) (5)
- Evaporation and Groundfall of JP-4 Jet Fuel Jettisoned by USAF Aircraft (1980) (5)
- A constrained maximum likelihood approach to evaluate the impact of dose metric on cancer risk assessment: application to β-chloroprene. (2014) (5)
- Food for Thought ... Can Case Study Approaches Speed Implementation of the NRC Report : “ Toxicity Testing in the 21 st Century : A Vision and a Strategy ? ” (2011) (5)
- An Alternative Exact Solution of the Two-Stage Clonal Growth Model of Cancer (1999) (5)
- Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment - A case study with parabens. (2022) (5)
- Physiologically-Based Pharmacokinetic (PBPK) Modeling and Risk Assessment (2011) (4)
- Drop Formation and Evaporation of JP-4 Fuel Jettisoned from Aircraft (1980) (4)
- Evaluation of semi-generic PBTK modeling for emergency risk assessment after acute inhalation exposure to volatile hazardous chemicals. (2015) (4)
- Bayesian Analysis of A Rat Formaldehyde DNA–Protein Cross-Link Model (2010) (4)
- Integration of Evidence to Evaluate the Potential for Neurobehavioral Effects Following Exposure to USFDA-Approved Food Colors. (2021) (4)
- A Rapid, Physiologically Based Method for Evaluating Candidate Chemical Warfare Agent Uptake Simulants (1985) (4)
- The Effect of Fuel Composition on Groundfall from Aircraft Fuel Jettisoning. (1981) (4)
- Weighing evidence and assessing uncertainties (2016) (4)
- PLETHEM – An interactive open-source platform for bridging the source-to-outcome continuum (2017) (4)
- Time‐ and concentration‐dependent genomic responses of the rat airway to inhaled nickel sulfate (2017) (4)
- An updated mode of action and human relevance framework evaluation for Formaldehyde-Related nasal tumors (2020) (4)
- The Conundrum of the PFOA human half-life, an international collaboration. (2022) (4)
- Extended Analysis and Evidence Integration of Chloroprene as a Human Carcinogen (2019) (4)
- Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation (2022) (3)
- Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats. (2020) (3)
- A Pharmacodynamic Model of Atrazine Effects on Estrous Cycle Characteristics in the Sprague-Dawley Rat (1998) (3)
- Estimating Minimally Effective Inducing Doses (EDOls) of TeDD in Livers of Rats and Humans Using Physiologically Based Pharmacokinetic Modeling (1997) (3)
- Development of a rat and human PBPK model for bromate and estimation of human equivalent concentrations in drinking water (2019) (3)
- Use ofin VitroData in PBPK Models: An Example ofin Vitrotoin VivoExtrapolation with Carbaryl (2012) (3)
- Physiologically based pharmacokinetic modeling software (2020) (3)
- Paraquat pharmacokinetics in primates and extrapolation to humans. (2021) (3)
- The TTC Data Mart: An interactive browser for threshold of toxicological concern calculations (2020) (3)
- Prenatal PCB-153 Exposure and Decreased Birth Weight: Verner et al. Respond (2014) (3)
- Physiologically Based Pharmacokinetic Modeling as a Tool to Interpret Human Biomonitoring Data (2005) (3)
- Kinetics of trichloroethylene in pregnant and lactating rats and rat pups (1987) (2)
- An integrated health risk assessment of contaminated sites under aleatory and epistemic uncertainties (2011) (2)
- Airborne Exposure to Arsenic Occurring in Coal Fly Ash (1999) (2)
- Interpreting biomonitoring data for di-n-butyl and di-(2-ethylhexyl) phthalate metabolites in urine using a physiologically based pharmacokinetic model and reverse dosimetry: Estimation of cumulative in utero exposure (2011) (2)
- Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010. (2010) (2)
- Probabilistic Reverse Dosimetry Modeling for Interpreting Biomonitoring Data (2010) (2)
- Conference on chemical risk assessment in the Department of Defense (DoD) : science, policy, and practice (1992) (2)
- Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids (2020) (2)
- Physiologically‐based pharmacokinetic modeling suggests similar bioavailability of Mn from diet and drinking water (2018) (2)
- Time-dependent Genomic Response in Primary Human Uroepithelial Cells Exposed to Arsenite for up to 60 Days. (2021) (2)
- Integrated human multi-organ culture plate for estimating systemic toxicity in vitro (2016) (1)
- Liver bioreactor as an in vitro metabolism system for quantitative in vitro to in vivo extrapolation (2014) (1)
- Considerations for a Biologically Based Risk Assessment for Arsenic (2015) (1)
- Physiologically-based pharmacokinetic scaling in retinoid developmental toxicity (2000) (1)
- Fuel Jettisoning by U.S. Air Force Aircraft. Volume II. Fuel Dump Listings. (1980) (1)
- Fuel Jettisoning by U.S. Air Force Aircraft. Volume I. Summary and Analysis. (1980) (1)
- Drop formation, evaporation modelling and environmental assessment of JP-4 fuel jettisoned from aircraft (1979) (1)
- Chapter 13:Modeling Manganese Kinetics for Human Health Risk Assessment (2014) (1)
- Computer Simulation of Chemical Carcinogenesis (1989) (1)
- Letter to the editor re: Cheng, YH., Chou, WC., Yang, YF. et al. Environ Sci Pollut Res (2017). https://doi.org/10.1007/s11356-017-0875-4 (2018) (1)
- Issues Surrounding Comparative Risk Assessments of Operational Materials: An Example with Air Force Hydraulic Fluids, (1993) (1)
- Application of Physiologically Based Pharmacokinetic Modeling in Health Risk Assessment (2010) (1)
- Modelling the effect of DMSA chelation therapy in patients intoxicated by lead (2014) (1)
- Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes Over Long Timeframes (2018) (1)
- Updating physiologically based pharmacokinetic models for manganese by incorporating rapid association/dissociation processes in tissues (2019) (1)
- Exposure Science: Pharmacokinetic Modeling (2011) (1)
- Modeling Kinetic Interactions of Chemical Mixtures (2010) (1)
- Toxicokinetics and Pharmacokinetic Modeling of Arsenic (2015) (1)
- S-078: Use of Physiologically-based Pharmacokinetic Models to Evaluate Epidemiologic Associations that may be Due to Reverse Causality (2012) (1)
- Integration of paraquat pharmacokinetic data across species using PBPK modelling. (2021) (1)
- Analysis of Transcriptomic Dose–Response Data for Toxicology and Risk Assessment (2011) (1)
- Limitations to benzene cancer risk assessment by Cox and Ricci. (1993) (1)
- Quantitative in vitro–in vivo extrapolations: Essential issues (2011) (1)
- Kinetics of metabolism of deltamethrin and cis- and trans-permethrin in vitro. Studies using rat and human liver microsomes, isolated rat hepatocytes and rat liver cytosol (2020) (0)
- Simulation modeling of PFAA exposure and pharmacokinetics (2009) (0)
- Alginate-encapsulated primary human hepatocyte culture system to increase the accuracy of the predicted in vivo half-life of low clearance compounds (2018) (0)
- List of contributors (2020) (0)
- Abeta systems pharmacology: An initial model for wild type mouse, monkey, and human (2011) (0)
- RE: Response to the Office of Environmental Health Hazard Assessment on comments related to Gentry et al. (2021). (2021) (0)
- Extrapolation of In Vitro Toxicity Assay Results to Provide Information Regarding In Vivo Exposures (2015) (0)
- Noncancer Effects of Trichioroethylene: Pharmacokinetics and Risk Assessment. (1998) (0)
- Streamlining metabolite identification and toxicity testing using alginate supported 3D culture of primary hepatocytes (2016) (0)
- SOC-I-01 Evaluation of the human relevance of anti-spermatogenic effects in rats using in vitro studies and in vitro to in vivo extrapolation (2022) (0)
- Using Pharmacokinetic modeling to enhance Mn risk assessment (2013) (0)
- Incorporation of a Recirculating Mobile Lipid Pool Description into the Cyclic Volatile Siloxane (cVMS) PBPK Model Captures Terminal Clearance of D4 after Repeated inhalation Exposure in F344 and SD Rats. (2022) (0)
- Workshop Session: Linking Early-Life Stages: The First Step toward Lifecourse Risk Assessment Approaches for Protecting Vulnerable Populations (2015) (0)
- Proceedings of the Conference on Chemical Risk Assessment in the DoD: science, Policy, and Practice Held in Dayton, Ohio on April 8-11, 1991 (1993) (0)
- Special aspects: Species differences, different life stages, exposure routes (2009) (0)
- Workshop Session: Linking Early-Life Stages: The First Step toward Lifecourse Risk Assessment Approaches for Protecting Vulnerable Populations (2015) (0)
- Recent Applications Of Physiologically Based Pharmacokinetic Modeling To Assess The Toxicity Of Mixtures: A Review (2023) (0)
- Physiologically based pharmacokinetics and methylene chloride cancer risk assessment considerations† (2020) (0)
- Occupational safety considerations with hydrazine (1992) (0)
- Use of Physiologically Based Pharmacokinetic Modeling to Evaluate Implications of Human Variability (2016) (0)
- P30—Development of rat gestation and lactation pBPK models for PFOA/PFOS (2012) (0)
- Modeling Liver and Kidney Cytotoxicity (2010) (0)
- Percutaneous Absorption of Chemical Vapors (1985) (0)
- On the incorporation of biokinetic and mechanistic data in modeling for risk assessment (2007) (0)
- LETTER TO EDITOR Response to "Accurate Risk-Based Chemical Screening Relies on Robust Exposure Estimates" (2012) (0)
- Overview: Integrated in vitro systems for toxicity assessment from repeated exposure (2016) (0)
- Validation of a model predicting the effect of 2,3-dimercaptosuccinic acid (DMSA) chelation therapy in patients intoxicated by lead (2017) (0)
- Response to “letter concerning: Clewell (2019) incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene.” (UIHT-2020-0053) (2020) (0)
- Evaluation of chloropentafluorobenzene as an intake simulant for chemical defense training. Final report, October 1991-October 1992 (1993) (0)
- In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI (2012) (0)
- Incorporation of rapid association/dissociation processes in tissues into the monkey and human physiologically based pharmacokinetic models for manganese (2022) (0)
- Liver bioreactor and incorporation of metabolism and biokinetics into the integrated cell-based toxicity system (2016) (0)
- Arsenic induced gene expression changes in primary human uroepithelial cells (2011) (0)
- CHAPTER 11. Big Data and Biokinetics (2019) (0)
- Trichloroacetate Tissue Dosimetry and PPAR alpha-Mediated Liver Cancer Induction by Trichioroethylene and Perchioroethylene (2000) (0)
- Physiologically based pharmacokinetic modeling of the pregnant rat: A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. (Reannouncement with new availability information). Interim report, April 1986-December 1988 (1989) (0)
- Assessing Bioactivity-Exposure Profiles of Fruits and Vegetables in the BioMAP Profiling System (2019) (0)
- PBPK modeling to evaluate maximum tolerated doses: A case study with 3-chloroallyl alcohol (2023) (0)
- Occupational safety considerations with hydrazine fuels (1992) (0)
- Toxic hazards research unit annual report 1991. Report for 16 November 1990-30 September 1991 (1992) (0)
- An in vitro approach to determine the human relevance of anti-spermatogenic effects of an industrial solvent in rat reproductive toxicity studies. (2021) (0)
- An in vitro approach to determine the human relevance of anti-spermatogenic effects of 4-methylmorpholine 4-oxide, monohydrate (NMMO) in rat reproductive toxicity studies. (2022) (0)
- Proceedings of the Conference on Toxicology: Applications of Advances in Toxicology to Risk Assessment. Held at Wright-Patterson AFB, Ohio on 19-21 May 1992 (1993) (0)
- 9:38 Predicting Children's Internal Exposure to Pyrethroids Using a Physiologically-Based Pharmacokinetic (2014) (0)
- The Effects of Manganese in Air (2004) (0)
- In vitro models and opensource toxicokinetic databases to support quantitative in vitro to in vivo extrapolation for human risk assessment (2018) (0)
- Relative contributions of endogenous and exogenous formaldehyde to formation of deoxyguanosine monoadducts and DNA-protein crosslink adducts of DNA in rat nasal mucosa (2022) (0)
- Comparison of dermal and inhalation routes of entry for organic chemicals (1992) (0)
- Response to Letter to Editor "Letter to the editors regarding "The Conundrum of the PFOA human half-life, an international collaboration." (2022) (0)
- CHAPTER 17:Systems Pharmacology Modeling (2015) (0)
- Abstract 373: Allometric scaling of the pharmacokinetics of pegylated liposomal anticancer drugs (2011) (0)
- An overview of PFAA pharmacokinetics (2012) (0)
- Updating the Biologically Based Dose Response Model for the Nasal Carcinogenicity of Inhaled Formaldehyde in the F344 Rat. (2023) (0)
- Incorporation of public exposure models into the PLETHEM pharmacokinetic framework (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Harvey J. Iii Clewell?
Harvey J. Iii Clewell is affiliated with the following schools:
